Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) Revenue (2022 - 2025)

Historic Revenue for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to $4.2 million.

  • Pharmaceuticals' Revenue rose 492.59% to $4.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $14.4 million, marking a year-over-year decrease of 3768.83%. This contributed to the annual value of $28.5 million for FY2024, which is 1576.79% down from last year.
  • Latest data reveals that Pharmaceuticals reported Revenue of $4.2 million as of Q2 2025, which was up 492.59% from $6.2 million recorded in Q1 2025.
  • Pharmaceuticals' 5-year Revenue high stood at $10.3 million for Q4 2022, and its period low was $3.4 million during Q1 2024.
  • Over the past 4 years, Pharmaceuticals' median Revenue value was $8.4 million (recorded in 2022), while the average stood at $7.5 million.
  • As far as peak fluctuations go, Pharmaceuticals' Revenue crashed by 5948.07% in 2024, and later soared by 8304.49% in 2025.
  • Pharmaceuticals' Revenue (Quarter) stood at $10.3 million in 2022, then tumbled by 33.0% to $6.9 million in 2023, then plummeted by 42.12% to $4.0 million in 2024, then rose by 4.93% to $4.2 million in 2025.
  • Its Revenue stands at $4.2 million for Q2 2025, versus $6.2 million for Q1 2025 and $4.0 million for Q2 2024.